Percheron Therapeutics ends clinical trial in Australia and Europe after data indicates no benefits after 6 months of treatment with avicursen (ATL1102)

Australian company Percheron Therapeutics released topline 6-month data from its Phase 2 study of avicursen in non-ambulatory individuals with Duchenne. The trial did not meet its primary endpoint, and there were no clear trends toward benefits on secondary outcomes. Therefore, Percheron is discontinuing the trial, and will share more analyses next year.   

READ MORE IN THE PRESS RELEASE ATTACHED